Identification of Potential Key Genes and Regulatory Markers in Essential Thrombocythemia Through Integrated Bioinformatics Analysis and Clinical Validation

References

• Tefferi A, Pardanani A, Solomon CG. Essential Thrombocythemia. N Engl J Med. 2019;381(22):2135–2144. doi:10.1056/NEJMcp1816082
   PubMed Web of Science ®Google Scholar
• Sankar K, Stein BL, Rampal RK. Thrombosis in the Philadelphia Chromosome-Negative Myeloproliferative Neoplasms. Cancer Treat Res. 2019;179:159–178.
   PubMedGoogle Scholar
• Ayres-Silva JP, Bonamino MH, Gouveia ME, et al. Genetic Alterations in Essential Thrombocythemia Progression to Acute Myeloid Leukemia: a Case Series and Review of the Literature. Front Oncol. 2018;8:32. doi:10.3389/fonc.2018.00032
   Web of Science ®Google Scholar
• O’Sullivan JM, Hamblin A, Yap C, et al. The poor outcome in high molecular risk, hydroxycarbamide-resistant/intolerant ET is not ameliorated by ruxolitinib. Blood. 2019;134(23):2107–2111. doi:10.1182/blood.2019001861
   Web of Science ®Google Scholar
• Lau WW, Hannah R, Green AR, Göttgens B. The JAK-STAT signaling pathway is differentially activated in CALR-positive compared with JAK2V617F-positive ET patients. Blood. 2015;125(10):1679–1681. doi:10.1182/blood-2014-12-618074
   Web of Science ®Google Scholar
• Milosevic Feenstra JD, Nivarthi H, Gisslinger H, et al. Whole-exome sequencing identifies novel MPL and JAK2 mutations in triple-negative myeloproliferative neoplasms. Blood. 2016;127(3):325–332. doi:10.1182/blood-2015-07-661835
   PubMed Web of Science ®Google Scholar
• Barrett T, Wilhite SE, Ledoux P, et al. NCBI GEO: archive for functional genomics data sets--update. Nucleic Acids Res. 2013;41(Database issue):D991–995. doi:10.1093/nar/gks1193
   PubMed Web of Science ®Google Scholar
• Clough E, Barrett T. The Gene Expression Omnibus Database. Methods Mol Biol. 2016;1418:93–110.
   PubMedGoogle Scholar
• Ghaedi H, Bastami M, Zare-Abdollahi D, et al. Bioinformatics prioritization of SNPs perturbing microRNA regulation of hematological malignancy-implicated genes. Genomics. 2015;106(6):360–366. doi:10.1016/j.ygeno.2015.10.004
   Web of Science ®Google Scholar
• Guo C, Li Z. Bioinformatics Analysis of Key Genes and Pathways Associated with Thrombosis in Essential Thrombocythemia. Med Sci Monit. 2019;25:9262–9271. doi:10.12659/MSM.918719
   PubMed Web of Science ®Google Scholar
• Hasselbalch HC, Thomassen M, Riley CH, et al. Whole blood transcriptional profiling reveals deregulation of oxidative and antioxidative defence genes in myelofibrosis and related neoplasms. Potential implications of downregulation of Nrf2 for genomic instability and disease progression. PLoS One. 2014;9(11):e112786. doi:10.1371/journal.pone.0112786
   PubMed Web of Science ®Google Scholar
• Gautier L, Cope L, Bolstad BM, Irizarry RA. affy--analysis of Affymetrix GeneChip data at the probe level. Bioinformatics. 2004;20(3):307–315. doi:10.1093/bioinformatics/btg405
   PubMed Web of Science ®Google Scholar
• Du P, Kibbe WA, Lin SM. lumi: a pipeline for processing Illumina microarray. Bioinformatics. 2008;24(13):1547–1548. doi:10.1093/bioinformatics/btn224
   PubMed Web of Science ®Google Scholar
• Carlson M. org.Hs.eg.db: genome wide annotation for Human: bioconductor; 2019.
   Google Scholar
• Ritchie ME, Phipson B, Wu D, et al. limma powers differential expression analyses for RNA-sequencing and microarray studies. Nucleic Acids Res. 2015;43(7):e47. doi:10.1093/nar/gkv007
   PubMed Web of Science ®Google Scholar
• Kolde R. pheatmap: pretty Heatmaps. Available from: https://CRAN.R-project.org/package=pheatmap. Accessed June 23, 2021.
   Google Scholar
• Slowikowski K. ggrepel: automatically Position Non-Overlapping Text Labels with ‘ggplot2ʹ. Available from: https://CRAN.R-project.org/package=ggrepel. Accessed June 23, 2021.
   Google Scholar
• Bindea G, Mlecnik B, Hackl H, et al. ClueGO: a Cytoscape plugin to decipher functionally grouped gene ontology and pathway annotation networks. Bioinformatics. 2009;25(8):1091–1093. doi:10.1093/bioinformatics/btp101
   PubMed Web of Science ®Google Scholar
• Janky R, Verfaillie A, Imrichová H, et al. iRegulon: from a gene list to a gene regulatory network using large motif and track collections. PLoS Comput Biol. 2014;10(7):e1003731. doi:10.1371/journal.pcbi.1003731
   PubMed Web of Science ®Google Scholar
• Szklarczyk D, Gable AL, Lyon D, et al. STRING v11: protein-protein association networks with increased coverage, supporting functional discovery in genome-wide experimental datasets. Nucleic Acids Res. 2019;47(D1):D607–607D613. doi:10.1093/nar/gky1131
   PubMed Web of Science ®Google Scholar
• Shannon P, Markiel A, Ozier O, et al. Cytoscape: a software environment for integrated models of biomolecular interaction networks. Genome Res. 2003;13(11):2498–2504. doi:10.1101/gr.1239303
   PubMed Web of Science ®Google Scholar
• Bader GD, Hogue CW. An automated method for finding molecular complexes in large protein interaction networks. BMC Bioinform. 2003;4:2. doi:10.1186/1471-2105-4-2
   PubMed Web of Science ®Google Scholar
• Chin CH, Chen SH, Wu HH, Ho CW, Ko MT, Lin CY. cytoHubba: identifying hub objects and sub-networks from complex interactome. BMC Syst Biol. 2014;8(Suppl 4):S11. doi:10.1186/1752-0509-8-S4-S11
   PubMed Web of Science ®Google Scholar
• Cotto KC, Wagner AH, Feng YY, et al. DGIdb 3.0: a redesign and expansion of the drug-gene interaction database. Nucleic Acids Res. 2018;46(D1):D1068–1068D1073. doi:10.1093/nar/gkx1143
   PubMedGoogle Scholar
• Tefferi A. Myeloproliferative neoplasms: a decade of discoveries and treatment advances. Am J Hematol. 2016;91(1):50–58. doi:10.1002/ajh.24221
   PubMed Web of Science ®Google Scholar
• Arber DA, Orazi A, Hasserjian R, et al. The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia. Blood. 2016;127(20):2391–2405. doi:10.1182/blood-2016-03-643544
   PubMed Web of Science ®Google Scholar
• Saeidi K. Myeloproliferative neoplasms: current molecular biology and genetics. Crit Rev Oncol Hematol. 2016;98:375–389.
   Web of Science ®Google Scholar
• Shirane S, Araki M, Morishita S, et al. JAK2, CALR, and MPL mutation spectrum in Japanese patients with myeloproliferative neoplasms. Haematologica. 2015;100(2):e46–48. doi:10.3324/haematol.2014.115113
   PubMed Web of Science ®Google Scholar
• Elala YC, Lasho TL, Gangat N, et al. Calreticulin variant stratified driver mutational status and prognosis in essential thrombocythemia. Am J Hematol. 2016;91(5):503–506. doi:10.1002/ajh.24338
   PubMed Web of Science ®Google Scholar
• Nangalia J, Green TR. The evolving genomic landscape of myeloproliferative neoplasms. Hematology Am Soc Hematol Educ Program. 2014;2014(1):287–296.
   Web of Science ®Google Scholar
• Tefferi A. Novel mutations and their functional and clinical relevance in myeloproliferative neoplasms: JAK2, MPL, TET2, ASXL1, CBL, IDH and IKZF1. Leukemia. 2010;24(6):1128–1138. doi:10.1038/leu.2010.69
   PubMed Web of Science ®Google Scholar
• Tefferi A, Pardanani A. Myeloproliferative Neoplasms: a Contemporary Review. JAMA Oncol. 2015;1(1):97–105. doi:10.1001/jamaoncol.2015.89
   PubMed Web of Science ®Google Scholar
• Lewis CM, Pegrum GD. Immune complexes in myeloproliferative disorders. Lancet. 1977;2(8049):1151–1153. doi:10.1016/s0140-6736(77)91539-2
   Google Scholar
• Marin Oyarzún CP, Carestia A, Lev PR, et al. Neutrophil extracellular trap formation and circulating nucleosomes in patients with chronic myeloproliferative neoplasms. Sci Rep. 2016;6:38738.
   PubMed Web of Science ®Google Scholar
• Marin Oyarzún CP, Heller PG. Platelets as Mediators of Thromboinflammation in Chronic Myeloproliferative Neoplasms. Front Immunol. 2019;10:1373. doi:10.3389/fimmu.2019.01373
   PubMed Web of Science ®Google Scholar
• Wolach O, Sellar RS, Martinod K, et al. Increased neutrophil extracellular trap formation promotes thrombosis in myeloproliferative neoplasms. Sci Transl Med. 2018;10(436):436. doi:10.1126/scitranslmed.aan8292
   Web of Science ®Google Scholar
• Hurtado-Nedelec M, Csillag-Grange MJ, Boussetta T, et al. Increased reactive oxygen species production and p47phox phosphorylation in neutrophils from myeloproliferative disorders patients with JAK2 (V617F) mutation. Haematologica. 2013;98(10):1517–1524. doi:10.3324/haematol.2012.082560
   PubMed Web of Science ®Google Scholar
• Dutzmann J, Daniel JM, Bauersachs J, Hilfiker-Kleiner D, Sedding DG. Emerging translational approaches to target STAT3 signalling and its impact on vascular disease. Cardiovasc Res. 2015;106(3):365–374. doi:10.1093/cvr/cvv103
   PubMed Web of Science ®Google Scholar
• Lee TI, Young RA. Transcriptional regulation and its misregulation in disease. Cell. 2013;152(6):1237–1251. doi:10.1016/j.cell.2013.02.014
   PubMed Web of Science ®Google Scholar
• Sanda T, Lawton LN, Barrasa MI, et al. Core transcriptional regulatory circuit controlled by the TAL1 complex in human T cell acute lymphoblastic leukemia. Cancer Cell. 2012;22(2):209–221. doi:10.1016/j.ccr.2012.06.007
   PubMed Web of Science ®Google Scholar
• Rinaldi CR, Martinelli V, Rinaldi P, Ciancia R, Del Vecchio L. GATA1 is overexpressed in patients with essential thrombocythemia and polycythemia vera but not in patients with primary myelofibrosis or chronic myelogenous leukemia. Leuk Lymphoma. 2008;49(7):1416–1419. doi:10.1080/10428190802087462
   PubMed Web of Science ®Google Scholar
• Nam S, Lim JS. Essential role of interferon regulatory factor 4 (IRF4) in immune cell development. Arch Pharm Res. 2016;39(11):1548–1555. doi:10.1007/s12272-016-0854-1
   PubMed Web of Science ®Google Scholar
• Man K, Gabriel SS, Liao Y, et al. Transcription Factor IRF4 Promotes CD8(+) T Cell Exhaustion and Limits the Development of Memory-like T Cells during Chronic Infection. Immunity. 2017;47(6):1129–1141.e5. doi:10.1016/j.immuni.2017.11.021
   PubMed Web of Science ®Google Scholar
• Negishi H, Ohba Y, Yanai H, et al. Negative regulation of Toll-like-receptor signaling by IRF-4. Proc Natl Acad Sci U S A. 2005;102(44):15989–15994. doi:10.1073/pnas.0508327102
   PubMed Web of Science ®Google Scholar
• Li Q, Yan Y, Liu J, et al. Toll-Like Receptor 7 Activation Enhances CD8+ T Cell Effector Functions by Promoting Cellular Glycolysis. Front Immunol. 2019;10:2191. doi:10.3389/fimmu.2019.02191
   PubMed Web of Science ®Google Scholar
• Wang C, Zhang L, Ke L, et al. Primary effusion lymphoma enhancer connectome links super-enhancers to dependency factors. Nat Commun. 2020;11(1):6318. doi:10.1038/s41467-020-20136-w
   Web of Science ®Google Scholar
• Pignarre A, Chatonnet F, Caron G, Haas M, Desmots-Loyer F, Fest T. Plasmablasts derive from CD23-negative activated B cells after the extinction of IL-4/STAT6 signaling and IRF4 induction. Blood. 2020.
   Web of Science ®Google Scholar
• Agnarelli A, Chevassut T, Mancini EJ. IRF4 in multiple myeloma-Biology, disease and therapeutic target. Leuk Res. 2018;72:52–58. doi:10.1016/j.leukres.2018.07.025
   Web of Science ®Google Scholar
• Chen M, Huang B, Zhu L, Chen K, Liu M, Zhong C. Structural and Functional Overview of TEAD4 in Cancer Biology. Onco Targets Ther. 2020;13:9865–9874. doi:10.2147/OTT.S266649
   PubMed Web of Science ®Google Scholar
• Lin KC, Moroishi T, Meng Z, et al. Regulation of Hippo pathway transcription factor TEAD by p38 MAPK-induced cytoplasmic translocation. Nat Cell Biol. 2017;19(8):996–1002. doi:10.1038/ncb3581
   PubMed Web of Science ®Google Scholar
• Wang C, Nie Z, Zhou Z, et al. The interplay between TEAD4 and KLF5 promotes breast cancer partially through inhibiting the transcription of p27Kip1. Oncotarget. 2015;6(19):17685–17697. doi:10.18632/oncotarget.3779
   Google Scholar
• Liu Y, Wang G, Yang Y, et al. Increased TEAD4 expression and nuclear localization in colorectal cancer promote epithelial-mesenchymal transition and metastasis in a YAP-independent manner. Oncogene. 2016;35(21):2789–2800. doi:10.1038/onc.2015.342
   PubMed Web of Science ®Google Scholar
• Gu C, Huang Z, Chen X, et al. TEAD4 promotes tumor development in patients with lung adenocarcinoma via ERK signaling pathway. Biochim Biophys Acta Mol Basis Dis. 2020;1866(12):165921. doi:10.1016/j.bbadis.2020.165921
   Web of Science ®Google Scholar
• Zhou Y, Huang T, Cheng AS, Yu J, Kang W, To KF. The TEAD Family and Its Oncogenic Role in Promoting Tumorigenesis. Int J Mol Sci. 2016;17(1).
   Web of Science ®Google Scholar
• Mitra P. Transcription regulation of MYB: a potential and novel therapeutic target in cancer. Ann Transl Med. 2018;6(22):443. doi:10.21037/atm.2018.09.62
   Web of Science ®Google Scholar
• Liu X, Xu Y, Han L, Yi Y. Reassessing the Potential of Myb-targeted Anti-cancer Therapy. J Cancer. 2018;9(7):1259–1266. doi:10.7150/jca.23992
   Web of Science ®Google Scholar
• Inoue K, Fry EA. Novel Molecular Markers for Breast Cancer. Biomark Cancer. 2016;8:25–42. doi:10.4137/BIC.S38394
   Google Scholar
• Malaterre J, Pereira L, Putoczki T, et al. Intestinal-specific activatable Myb initiates colon tumorigenesis in mice. Oncogene. 2016;35(19):2475–2484. doi:10.1038/onc.2015.305
   PubMed Web of Science ®Google Scholar
• Cao L, Mitra P, Gonda TJ. The mechanism of MYB transcriptional regulation by MLL-AF9 oncoprotein. Sci Rep. 2019;9(1):20084. doi:10.1038/s41598-019-56426-7
   Web of Science ®Google Scholar
• Wang X, Angelis N, Thein SL. MYB - A regulatory factor in hematopoiesis. Gene. 2018;665:6–17. doi:10.1016/j.gene.2018.04.065
   Web of Science ®Google Scholar
• Zuber J, Rappaport AR, Luo W, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628–1640. doi:10.1101/gad.17269211
   PubMed Web of Science ®Google Scholar
• Tapper W, Jones AV, Kralovics R, et al. Genetic variation at MECOM, TERT, JAK2 and HBS1L-MYB predisposes to myeloproliferative neoplasms. Nat Commun. 2015;6:6691. doi:10.1038/ncomms7691
   PubMed Web of Science ®Google Scholar
• Kastner P, Chan S. PU.1: a crucial and versatile player in hematopoiesis and leukemia. Int J Biochem Cell Biol. 2008;40(1):22–27. doi:10.1016/j.biocel.2007.01.026
   Web of Science ®Google Scholar
• Delestré L, Cui H, Esposito M, et al. Senescence is a Spi1-induced anti-proliferative mechanism in primary hematopoietic cells. Haematologica. 2017;102(11):1850–1860. doi:10.3324/haematol.2016.157636
   PubMed Web of Science ®Google Scholar
• Seki M, Kimura S, Isobe T, et al. Recurrent SPI1 (PU.1) fusions in high-risk pediatric T cell acute lymphoblastic leukemia. Nat Genet. 2017;49(8):1274–1281. doi:10.1038/ng.3900
   PubMed Web of Science ®Google Scholar
• Sasaki I, Kaisho T. Transcriptional control of dendritic cell differentiation. Curr Top Microbiol Immunol. 2014;381:257–278. doi:10.1007/82_2014_378
   Web of Science ®Google Scholar
• Du W, Xu X, Niu Q, et al. Spi-B-Mediated Silencing of Claudin-2 Promotes Early Dissemination of Lung Cancer Cells from Primary Tumors. Cancer Res. 2017;77(18):4809–4822. doi:10.1158/0008-5472.CAN-17-0020
   Web of Science ®Google Scholar
• Takagi Y, Shimada K, Shimada S, et al. SPIB is a novel prognostic factor in diffuse large B-cell lymphoma that mediates apoptosis via the PI3K-AKT pathway. Cancer Sci. 2016;107(9):1270–1280. doi:10.1111/cas.13001
   Web of Science ®Google Scholar
• Montes-Moreno S, Ramos-Medina R, Martínez-López A, et al. SPIB, a novel immunohistochemical marker for human blastic plasmacytoid dendritic cell neoplasms: characterization of its expression in major hematolymphoid neoplasms. Blood. 2013;121(4):643–647. doi:10.1182/blood-2012-08-447599
   Web of Science ®Google Scholar
• Ho YJ, Lin YM, Huang YC, Yeh KT, Lin LI, Lu JW. Tissue microarray-based study of hepatocellular carcinoma validating SPIB as potential clinical prognostic marker. Acta Histochem. 2016;118(1):38–45. doi:10.1016/j.acthis.2015.11.005
   Web of Science ®Google Scholar
• Forrester AM, Grabher C, McBride ER, et al. NUP98-HOXA9-transgenic zebrafish develop a myeloproliferative neoplasm and provide new insight into mechanisms of myeloid leukaemogenesis. Br J Haematol. 2011;155(2):167–181. doi:10.1111/j.1365-2141.2011.08810.x
   Web of Science ®Google Scholar
• Fluhr S, Boerries M, Busch H, et al. CREBBP is a target of epigenetic, but not genetic, modification in juvenile myelomonocytic leukemia. Clin Epigenetics. 2016;8:50. doi:10.1186/s13148-016-0216-3
   PubMed Web of Science ®Google Scholar
• Crispino JD, Horwitz MS. GATA factor mutations in hematologic disease. Blood. 2017;129(15):2103–2110. doi:10.1182/blood-2016-09-687889
   PubMed Web of Science ®Google Scholar
• Vainchenker W, Raslova H. Megakaryocyte polyploidization: role in platelet production. Platelets. 2020;31(6):707–716. doi:10.1080/09537104.2019.1667497
   PubMed Web of Science ®Google Scholar
• Zhang L, Li J, Xu H, et al. Myc-Miz1 signaling promotes self-renewal of leukemia stem cells by repressing Cebpα and Cebpδ. Blood. 2020;135(14):1133–1145.
   Web of Science ®Google Scholar
• Lussana F, Rambaldi A. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017;85:58–63. doi:10.1016/j.jaut.2017.06.010
   PubMed Web of Science ®Google Scholar
• Čokić VP, Mitrović-Ajtić O, Beleslin-čokić BB, et al. Proinflammatory Cytokine IL-6 and JAK-STAT Signaling Pathway in Myeloproliferative Neoplasms. Mediators Inflamm. 2015;2015:453020. doi:10.1155/2015/453020
   Web of Science ®Google Scholar
• Johnson DE, O’Keefe RA, Grandis JR. Targeting the IL-6/JAK/STAT3 signalling axis in cancer. Nat Rev Clin Oncol. 2018;15(4):234–248.
   PubMed Web of Science ®Google Scholar
• Braun LM, Zeiser R. Immunotherapy in Myeloproliferative Diseases. Cells. 2020;9(6):1559. doi:10.3390/cells9061559
   Google Scholar
• Kamata T, Dankort D, Kang J, et al. Hematopoietic expression of oncogenic BRAF promotes aberrant growth of monocyte-lineage cells resistant to PLX4720. Mol Cancer Res. 2013;11(12):1530–1541.
   Web of Science ®Google Scholar
• Williams DA. Pairing JAK with MEK for improved therapeutic efficiency in myeloproliferative disorders. J Clin Invest. 2019;129(4):1519–1521. doi:10.1172/JCI127582
   Web of Science ®Google Scholar
• Xie HJ, Lundgren S, Broberg U, Finnström N, Rane A, Hassan M. Effect of cyclophosphamide on gene expression of cytochromes p450 and beta-actin in the HL-60 cell line. Eur J Pharmacol. 2002;449(3):197–205. doi:10.1016/S0014-2999(02)01995-7
   Web of Science ®Google Scholar
• Craver B, Nguyen Q, Ramanathan G, Fleischman AG. Single-Cell RNA-Seq to Assess Differential Responses to Tnfα in Human Hematopoietic Stem and Progenitor Cells in Myeloproliferative Neoplasm. Blood. 2019;134(Supplement_1):2518. doi:10.1182/blood-2019-123480
   Web of Science ®Google Scholar
• Kakiuchi S, Ohara S, Ogata S, Miura D, Kasahara Y, Izawa Y. Flow cytometric analyses on lineage-specific cell surface antigens of rat bone marrow to seek potential myelotoxic biomarkers: status after repeated dose of 5-fluorouracil. J Toxicol Sci. 2004;29(2):101–111. doi:10.2131/jts.29.101
   Google Scholar
• Dhanyamraju PK, Iyer S, Smink G, et al. Transcriptional Regulation of Genes by Ikaros Tumor Suppressor in Acute Lymphoblastic Leukemia. Int J Mol Sci. 2020;21(4):1377. doi:10.3390/ijms21041377
   Web of Science ®Google Scholar
• Maude SL, Tasian SK, Vincent T, et al. Targeting JAK1/2 and mTOR in murine xenograft models of Ph-like acute lymphoblastic leukemia. Blood. 2012;120(17):3510–3518. doi:10.1182/blood-2012-03-415448
   PubMed Web of Science ®Google Scholar
• Nguyen HM, Gotlib J. Insights into the molecular genetics of myeloproliferative neoplasms. Am Soc Clin Oncol Educ Book. 2012;411–418. doi:10.14694/EdBook_AM.2012.32.85
   Google Scholar
• Krönke J, Udeshi ND, Narla A, et al. Lenalidomide causes selective degradation of IKZF1 and IKZF3 in multiple myeloma cells. Science. 2014;343(6168):301–305. doi:10.1126/science.1244851
   PubMed Web of Science ®Google Scholar
• Arulogun SO, Choong HL, Taylor D, et al. JAK1 somatic mutation in a myeloproliferative neoplasm. Haematologica. 2017;102(8):e324–324e327. doi:10.3324/haematol.2017.170266
   PubMed Web of Science ®Google Scholar
• Czech J, Cordua S, Weinbergerova B, et al. JAK2V617F but not CALR mutations confer increased molecular responses to interferon-α via JAK1/STAT1 activation. Leukemia. 2019;33(4):995–1010. doi:10.1038/s41375-018-0295-6
   Web of Science ®Google Scholar